Format

Send to

Choose Destination
Mol Cell Endocrinol. 2009 Jan 15;297(1-2):137-40. doi: 10.1016/j.mce.2008.11.018. Epub 2008 Nov 25.

Molecular, pharmacological and clinical aspects of liraglutide, a once-daily human GLP-1 analogue.

Author information

1
Department of Diabetes and Endocrinology, Royal Surrey County Hospital, Egerton Road, Guildford GU2 7XX, UK. drj@royalsurrey.nhs.uk

Abstract

Liraglutide, a human glucagon-like peptide 1 (GLP-1) analogue with high homology to native GLP-1, has structural modifications sufficient to amend pharmacokinetics for once-daily administration without compromising biological activity. Data from large, controlled, clinical studies have confirmed the therapeutic profile of liraglutide, with robust reductions in HbA(1c), low risk of hypoglycaemia and clinically relevant reductions in body weight and systolic blood pressure.

PMID:
19041364
DOI:
10.1016/j.mce.2008.11.018
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center